{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T13:42:40Z","timestamp":1778593360884,"version":"3.51.4"},"reference-count":34,"publisher":"The Journal of Rheumatology","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2016,12]]},"abstract":"<jats:sec><jats:title>Objective.<\/jats:title><jats:p>Assess 5-year golimumab (GOL) safety in rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods.<\/jats:title><jats:p>Subcutaneous (SC) GOL (50 mg or 100 mg every 4 weeks) was evaluated in phase 3 trials of patients with active RA, PsA, and AS. Safety data through Year 5 were pooled across 3 RA trials [1 each evaluating methotrexate (MTX)-naive, MTX-experienced, and antitumor necrosis factor (TNF)-experienced patients], 1 PsA trial, and 1 AS trial. Data summarized was derived from both placebo-controlled (through weeks 24\u201352) and uncontrolled study periods. For adverse events (AE) of special interest [serious infections (SI), opportunistic infections (OI), deaths, malignancies, demyelination, tuberculosis (TB)], incidence per 100 patient-years (pt-yrs) was determined.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results.<\/jats:title><jats:p>Across all trials, 639 patients received placebo and 2228 received SC GOL 50 mg only (n = 671), 50 mg and 100 mg (n = 765), or 100 mg only (n = 792). Safety followup extended for averages of 28.5 and 203.2 weeks for placebo and GOL, respectively. Respective placebo and GOL AE incidence\/100 pt-yrs (95% CI) through Year 5 were 4.86 (2.83\u20137.78) and 3.29 (2.92\u20133.69) for SI, 0.00 (0.00\u20130.86) and 0.23 (0.14\u20130.35) for TB, 0.00 (0.00\u20130.86) and 0.22 (0.13\u20130.34) for OI, 0.00 (0.00\u20130.86) and 0.10 (0.05\u20130.20) for lymphoma, 0.00 (0.00\u20130.86) and 0.08 (0.03\u20130.17) for demyelination, and 0.29 (0.01\u20131.59) and 0.41 (0.29\u20130.57) for death. TB, OI, lymphoma, and demyelination incidence appeared to be higher among patients receiving GOL 100 mg only.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion.<\/jats:title><jats:p>SC GOL safety through Year 5 remained consistent with previously reported Year 3 findings and with other TNF antagonists. Numerically higher incidences of TB, OI, lymphoma, and demyelination were observed with 100 mg versus 50 mg. <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"Clinicaltrials.gov\" ext-link-type=\"uri\" xlink:type=\"simple\">Clinicaltrials.gov<\/jats:ext-link> identifiers: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT00264537\">NCT00264537<\/jats:ext-link> (GO-BEFORE), <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT00264550\">NCT00264550<\/jats:ext-link> (GO-FORWARD), <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT00299546\">NCT00299546<\/jats:ext-link> (GO-AFTER), <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT00265096\">NCT00265096<\/jats:ext-link> (GO-REVEAL), and <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT00265083\">NCT00265083<\/jats:ext-link> (GO-RAISE).<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.160420","type":"journal-article","created":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T21:25:20Z","timestamp":1478035520000},"page":"2120-2130","source":"Crossref","is-referenced-by-count":37,"title":["Five-year Safety Data from 5 Clinical Trials of Subcutaneous Golimumab in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis"],"prefix":"10.3899","volume":"43","author":[{"given":"Jonathan","family":"Kay","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roy","family":"Fleischmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward","family":"Keystone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth C.","family":"Hsia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiying","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neil","family":"Goldstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00fcrgen","family":"Braun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2262","published-online":{"date-parts":[[2016,11,1]]},"reference":[{"key":"2018112909362996000_43.12.2120.1","unstructured":"Janssen BiotechInc . Simponi (golimumab) injection, for subcutaneous use. Highlights of prescribing information. [Internet. Accessed September 29, 2016.] Available from: www.simponi.com\/shared\/product\/simponi\/prescribing-information.pdf"},{"key":"2018112909362996000_43.12.2120.2","unstructured":"European Medicines Agency . Simponi (golimumab). Summary of product characteristics. [Internet. Accessed September 6, 2016.] Available from: www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000992\/WC500052368.pdf"},{"key":"2018112909362996000_43.12.2120.3","unstructured":"AbbVie, Inc . Humira (adalimumab) injection, for subcutaneous use. Highlights of prescribing information. [Internet. Accessed September 6, 2016.] Available from: www.rxabbvie.com\/pdf\/humira.pdf"},{"key":"2018112909362996000_43.12.2120.4","unstructured":"UCB, Inc . Cimzia (certolizumab pegol), lyophilized powder or solution for subcutaneous use. Highlights of prescribing information. [Internet. Accessed September 29, 2016.] Available from: www.cimzia.com\/assets\/pdf\/Prescribing_Information.pdf"},{"key":"2018112909362996000_43.12.2120.5","unstructured":"Immunex Corporation . Enbrel (etanercept), solution for subcutaneous use. Highlights of prescribing information. [Internet. Accessed September 29, 2016.] Available from: pi.amgen.com\/united_states\/enbrel\/derm\/enbrel_pi.pdf"},{"key":"2018112909362996000_43.12.2120.6","unstructured":"Janssen Biotech Inc . Remicade (infliximab), lyophilized concentrate for intravenous injection. Highlights of prescribing information. [Internet. Accessed September 6, 2016.] Available from: www.remicade.com\/shared\/product\/remicade\/prescribing-information.pdf"},{"key":"2018112909362996000_43.12.2120.7","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204195"},{"key":"2018112909362996000_43.12.2120.8","doi-asserted-by":"publisher","DOI":"10.1002\/art.24638"},{"key":"2018112909362996000_43.12.2120.9","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1002\/acr.22072","article-title":"Golimumab, a human anti\u2013tumor necrosis factor monoclonal antibody, injected subcutaneously every 4 weeks in patients with active rheumatoid arthritis who had never taken methotrexate: 1-year and 2-year clinical, radiologic, and physical function findings of a phase III, multicenter, randomized, double-blind, placebo-controlled study","volume":"65","author":"Emery","year":"2013","journal-title":"Arthritis Care Res"},{"key":"2018112909362996000_43.12.2120.10","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1002\/acr.22759","article-title":"Efficacy and safety of subcutaneous golimumab in methotrexate-naive patients with rheumatoid arthritis: five-year results of a randomized clinical trial","volume":"68","author":"Emery","year":"2016","journal-title":"Arthritis Care Res"},{"key":"2018112909362996000_43.12.2120.11","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.099010"},{"key":"2018112909362996000_43.12.2120.12","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.116319"},{"key":"2018112909362996000_43.12.2120.13","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.120584"},{"key":"2018112909362996000_43.12.2120.14","doi-asserted-by":"crossref","first-page":"298","DOI":"10.3899\/jrheum.150712","article-title":"Safety and efficacy of subcutaneous golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: final 5-year results of the GO-FORWARD trial","volume":"43","author":"Keystone","year":"2015","journal-title":"J Rheumatol"},{"key":"2018112909362996000_43.12.2120.15","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60506-7"},{"key":"2018112909362996000_43.12.2120.16","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200956"},{"key":"2018112909362996000_43.12.2120.17","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-015-0516-6"},{"key":"2018112909362996000_43.12.2120.18","doi-asserted-by":"publisher","DOI":"10.1002\/art.24403"},{"key":"2018112909362996000_43.12.2120.19","doi-asserted-by":"publisher","DOI":"10.1002\/art.34436"},{"key":"2018112909362996000_43.12.2120.20","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202035"},{"key":"2018112909362996000_43.12.2120.21","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204902"},{"key":"2018112909362996000_43.12.2120.22","doi-asserted-by":"publisher","DOI":"10.1002\/art.23969"},{"key":"2018112909362996000_43.12.2120.23","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2011.154799"},{"key":"2018112909362996000_43.12.2120.24","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-205862"},{"key":"2018112909362996000_43.12.2120.25","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780380602"},{"key":"2018112909362996000_43.12.2120.26","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780270401"},{"key":"2018112909362996000_43.12.2120.27","first-page":"2286","article-title":"A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index","volume":"21","author":"Garrett","year":"1994","journal-title":"J Rheumatol"},{"key":"2018112909362996000_43.12.2120.28","unstructured":"National Cancer Institute: Surveillance, Epidemiology, and End Results. Overview of the SEER program. [Internet. Accessed September 6, 2016.] Available from: SEER.cancer.gov\/about\/overview.html"},{"key":"2018112909362996000_43.12.2120.29","first-page":"238","article-title":"Assessment of long-term safety and efficacy of etanercept in a 5-year extension study in patients with rheumatoid arthritis","volume":"29","author":"Klareskog","year":"2011","journal-title":"Clin Exp Rheumatol"},{"key":"2018112909362996000_43.12.2120.30","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kev249"},{"key":"2018112909362996000_43.12.2120.31","doi-asserted-by":"publisher","DOI":"10.1186\/ar2404"},{"key":"2018112909362996000_43.12.2120.32","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1136\/bmj.317.7152.180","article-title":"Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study","volume":"317","author":"Baecklund","year":"1998","journal-title":"BMJ"},{"key":"2018112909362996000_43.12.2120.33","doi-asserted-by":"publisher","DOI":"10.1002\/art.21675"},{"key":"2018112909362996000_43.12.2120.34","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-0012.2008.00904.x"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.160420","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,11,29]],"date-time":"2018-11-29T14:12:56Z","timestamp":1543500776000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.160420"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,1]]},"references-count":34,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2016,12,1]]},"published-print":{"date-parts":[[2016,12]]}},"alternative-id":["10.3899\/jrheum.160420"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.160420","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,1]]}}}